In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01430390
Recruitment Status : Recruiting
First Posted : September 8, 2011
Last Update Posted : May 2, 2018
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Brief Summary:
The purpose of this study is to test the safety of giving the patient special cells from a donor called "Modified T-cells". The goal is to find a safe dose of modified T-cells for patients with relapsed B cell leukemia or lymphoma after a blood SCT. The investigators also want to find out what effects these T-cells have on the patient and the disease.

Condition or disease Intervention/treatment Phase
Acute Lymphocytic Leukemia Lymphoma Biological: Biological/Genetically Modified T cells Drug: Cyclophosphamide-based chemotherapy Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Dose Escalation Trial Using In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
Study Start Date : September 2011
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : September 2019

Arm Intervention/treatment
Experimental: Biological/Genetically Modified T cells
Patients with persistent minimal residual disease (+MRD)/ relapsed/refractory CD19+ malignancy will receive EBV specific cytotoxic T-cells (EBV-CTLs) genetically modified ex vivo to express the CD19-specific 19-28z chimeric artificial receptor.
Biological: Biological/Genetically Modified T cells
Following completion of the chemotherapy, genetically modified T cells will be given intravenously at one of 3 dose levels. After the infusion patients will be monitored clinically and with serial blood and marrow evaluations to assess toxicity, therapeutic effects, and the in-vivo survival of the genetically modified T-cells.

Drug: Cyclophosphamide-based chemotherapy
Recommended chemotherapy regimen consists of single agent Cyclophosphamide at a dose of 3000 mg/m2/dose IV over 1 hour or 1500mg/m2/dose x 2 doses given daily over 1 hour given for 2 days (patients may received reduced dose of cyclophosphamide based on the clinical status of the patient at discretion of the treating physician and with written approval by the MSKCC PI of this study).

Primary Outcome Measures :
  1. Evaluate the safety/persistence of escalating doses of allogeneic EBV specific CTL modified to express artificial T cell receptors targeting CD19 molecule given for persistence or relapse of B-Cell ALL post allogeneic HSCT. [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. To assess the effects of the adoptively transferred CD19 specific T-cells on the progression of leukemia. [ Time Frame: 3 years ]
  2. To quantitate the number of chimeric antigen receptor (CAR) positive T-cells in the blood at defined intervals post infusion in order to determine their survival and proliferation in the host. [ Time Frame: 3 years ]
  3. To assess long-term status of treated patients [ Time Frame: 15 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • History of CD19+ malignancy with evidence of relapse or persistent MRD following autologous or allogenic hematopoietic stem cell transplantation. (cohort 1)
  • Relapse on this protocol is detection of CD19+ malignancies in bone marrow ≥ 5% or extramedullary lesion by morphology cytogenetics, molecular, radiographic and/or flow cytometry.
  • Persistent minimal residual disease after transplantation must be demonstrated by morphology karyotype, FISH, flow cytometry or RT-PCR.
  • History of relapsed or refractory CD19+ malignancies (e.g. Non Hodgkin Lymphoma) who have failed prior treatment and require autologous hematopoietic stem cell transplant. Evidence of disease not required. (cohort 2)
  • No age restriction for patients
  • KPS or Lansky score > or = to 50
  • Renal function (measured prior to conditioning chemotherapy)
  • Hepatic function (measured prior to conditioning chemotherapy):
  • AST ≤ 5 x the institutional ULN Elevation secondary to leukemic involvement is not an exclusion criterion. Leukemic involvement will be determined by the presence of progressive relapse defined by escalating bone marrow or peripheral blood leukemia blasts within the previous month and the absence of initiation of know hepatotoxic medication (e.g. azoles).
  • Total bilirubin ≤ 2.5 x the institutional ULN
  • Adequate cardiac function (e.g. LVEF ≥ 40%) as assessed by ECHO or MUGA or other similar cardia imaging performed within 1 month of treatment.
  • Pulmonary function (measured prior to treatment):
  • Oxygen saturation ≥ 90% on room air

Donor Eligibility:

  • The patient's HSCT donor, or if HSCT donor is not available a third party donor, must consent to a leukapheresis or whole blood donation(s) obtained at one or more phlebotomies which, in aggregate, will total approximately 250 ml for adults and no more than 5ml/kg per draw from pediatric donors.
  • Related donors <18 years of age requiring placement of a leukapheresis catheter will donate peripheral blood collected by phlebotomy (including a unit of blood if weight permits) and shall not undergo catheter placement for leukapheresis as this is considered above minimal risk to the donor.
  • There is no upper age limit for a donors. However, the minimum age for a related donor is 7 years as this is the youngest age a person can be considered capable of giving assent to participate in a research study.
  • Evidence of prior sensitization to EBV by EBV serology testing (seropositive)
  • Donor's high resolution HLA typing must be available for review
  • CBC within one week of donation. Results of tests must be within a range that would not preclude donating blood or undergoing leukapheresis.
  • Serologic testing for transmissible diseases will be performed as per institutional guidelines adopted from extant NMDP and FACT guidelines. Donors should be considered eligible to donate leukapheresis or blood based on these guidelines (i.e. blood donation guidelines)

Exclusion Criteria:

  • Patients with active HIV, hepatitis B or hepatitis C infection.
  • Patients with any concurrent active malignancies as defined by malignancies requiring any therapy other than expectant observation.
  • Females who are pregnant.
  • Patients will be excluded if they have isolated extra-medullary relapse of ALL.
  • Previous infusion of CD19 CAR T cells at another institution
  • Patients with active (grade 2-4) acute graft versus host disease (GVHD), chronic GVHD or an overt autoimmune disease (e.g. hemolytic anemia) requiring glucocorticosteroid treatment (>0.5 mg/kg/day prednisone or its equivalent) as treatment
  • Active central nervous system (CNS) leukemia, as defined by unequivocal morphologic evidence of lymphoblasts in the cerebrospinal fluid (CSF) or symptomatic CNS leukemia (i.e. cranial nerve palsies or other significant neurologic dysfunction) within 28 days of treatment. Prophylactic intrathecal medication is not a reason for exclusion.
  • Adult patients (≥18 years old) with the following cardiac conditions will be excluded:
  • New York Heart Association (NYHA) stage III or IV congestive heart failure
  • Myocardial infarction ≤ 6months prior to enrollment
  • History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration.
  • History of severe non-ischemic cardiomyopathy with EF ≤20%
  • Uncontrolled, symptomatic, intercurrent illness including but not limited to infection, psychiatric illness, or social situations that would limit compliance with study requirements or in the opinion of the treating investigator would pose an unacceptable risk to the subject.
  • Prior neurologic toxicity to previous immunotherapy
  • Preceding and/or ongoing organ dysfunction or other co-morbidity including but not limited to uncontrolled infection that would impair the patient's ability to endure known side effects of cytokine release syndrome or neurological toxicity
  • Recent prior therapy: Systematic chemotherapy less than 2 weeks prior to infusion.
  • Recent prior therapy: Systematic chemotherapy less than 2 weeks prior to infusion. Exceptions:

    • There is no time restriction in regard to prior intrathecal chemotherapy provided tere is complete recovery from any acute toxic effects of such.
    • Subjects receiving hydroxyurea or oral maintenance chemotherapy may be enrolled provided there has been no increase in dose for at least 2 weeks prior to starting apheresis or treatment
    • Subjects receiving steroid therapy at physiological replacement doses only are allowed provided there has been no increase in dose for at least 2 weeks prior to subject starting apheresis or treatment.
    • Subjects must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met. Cytopenias deemed to be disease-related and not therapy-related are exempt from this exclusion.
  • Rapidly progressive disease that in the estimation of the treating physician would compromise ability to complete study therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01430390

Contact: Kevin Curran, MD 212-639-5836
Contact: Nancy Kernan, MD 212-639-7250

United States, New York
Memorial Sloan Kettering Cancer Center 1275 York Avenue Recruiting
New York, New York, United States, 10065
Contact: Kevin Curran, MD    212-639-5836      
Contact: Nancy Kernan, MD    212-639-7250      
Principal Investigator: Kevin Curran, MD         
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Principal Investigator: Kevin Curran, MD Memorial Sloan Kettering Cancer Center

Additional Information:
Responsible Party: Memorial Sloan Kettering Cancer Center Identifier: NCT01430390     History of Changes
Other Study ID Numbers: 11-038
First Posted: September 8, 2011    Key Record Dates
Last Update Posted: May 2, 2018
Last Verified: April 2018

Keywords provided by Memorial Sloan Kettering Cancer Center:
In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic
T-Lymphocytes (EBV-CTLs)
CD19 specific T-cells

Additional relevant MeSH terms:
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists